Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Chairs and members

Chair (2024–2027 term)Igor Aurer (education and scientific meetings co-lead) – University Hospital Centre Zagreb, University of Zagreb and KroHem, Croatia

Co-chair (2024–2027 term)Martin Dreyling (guidelines lead) – University Hospital Grosshadern, Ludwig Maximilian University and GLA, Germany

SWG Executive Board members (2024–2027 term)
Kim Linton (scientific secretary) –…

EHA Pediatric Hemato-Oncology Course 2024

Join us in Sorrento to develop your problem-solving skills and exchange ideas in a friendly and supportive environment. DatesApril 10–13, 2024. LocationGrand Hotel Riviera, Sorrento, Italy.

Highlights from the SWG

The following activities, which were organized by EMN, also constitute contributions to and participation in the work of the EHA SWG on Multiple Myeloma.

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

EHA Statement on COVID-19 Vaccines

EHA-SWG Scientific Meetings

On this page, you can browse and/or download the interactive EHA-SWG Scientific Meetings Sponsor Program, which will be released early December.